Edwards said continuing operations net sales for Q3 2024 were $1,354.4 million, up 8.9% from $1,243.4 million a year earlier, and up 9.6% on a constant currency basis, which excludes the effect of foreign exchange.

1. 01

   Edwards said continuing operations net sales for Q3 2024 were $1,354.4 million, up 8.9% from $1,243.4 million a year earlier, and up 9.6% on a constant currency basis, which excludes the effect of foreign exchange.

2. 02

   The company said it completed the sale of Critical Care in Q3. Income from discontinued operations, net of tax, was $2,707.3 million, net income was $3,069.4 million, and diluted earnings per share were $5.13. Net income from continuing operations was $362.1 million.

3. 03

   Edwards said adjusted EPS for Q3 was $0.67 and that its full-year sales growth guidance of 8 to 10% remains unchanged. The company said it expects Q4 sales of $1.33 to $1.39 billion and EPS of $0.53 to $0.57.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call. Some paragraphs were omitted because their support in the source could not be confirmed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.